Breaking News

Amgen Accelerates Expansion Plans in China with $2.7B Deal

Will collaborate with BeiGene to advance 20 medicines from Amgen's innovative oncology pipeline in China and globally

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen’s expansion plans in China. BeiGene is a research-based, oncology-focused biotechnology company with an established and experienced team in China, including a 700-person commercial organization and a 600-person clinical development organization. As part of the collaboration Amgen will acquire a 20.5% stake in BeiGene for approximately $2.7 billion in cash. “This strategic collabo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters